Feds approve Pfizer pandemic swine vaccine
Pfizer Animal Health has gained full licensure from the U.S. Department of Agriculture (USDA) for FluSure Pandemic, according to a company report.
The vaccine helps pork producers protect their herds from the pandemic H1N1 (pH1N1) strain of Swine Influenza Virus (SIV).
In 2009, Pfizer Animal Health was the first manufacturer to gain a conditional license for a vaccine for this new flu strain. During this period of conditional licensure, Pfizer Animal Health conducted additional research to further support the safety and efficacy of the product.
“In a challenge study, the vaccine helped reduce both viral shedding and lung lesions,” said Michael Kuhn, DVM, MBA, manager, veterinary operations for Pfizer Animal Health.
Pfizer Animal Health is packaging the full licensed vaccine under the FluSure Pandemic name. The new vaccine adds another valuable swine influenza management tool to Pfizer Animal Health’s FluSure XP Defense System.
“Pfizer Animal Health is committed to monitoring swine influenza viruses and bringing to the market vaccines that help protect against SIV strains circulating in pork production systems today,” says Kuhn in a Pfizer report.
FluSure Pandemic is labeled for vaccination of healthy swine, including pregnant sows and gilts, three weeks of age or older as an aid in preventing nasal shedding and reducing lung lesions caused by the SIV subtype pH1N1. The new vaccine is available in 50-dose and 250-dose sizes.
Amphigen, the adjuvant in FluSure Pandemic, helps stimulate immune responses, using the animal’s natural defense system to help fight disease. Amphigen was developed for excellent syringeability at any temperature, making vaccination easier.
Producers are advised to consult their veterinarian, as well as continue to follow American Association of Swine Veterinarians and National Pork Producers Council recommendations for routine flu preventive measures.